MedTrace Logo

Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection

NCT00277576 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2008-11-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to reduce hepatitis B disease.

Conditions

Interventions

BIOLOGICAL

ppdpSC18 administered by PMED

Sponsors & Collaborators

  • PowderMed

    lead INDUSTRY

Principal Investigators

  • Henry LY Chan · Prince of Wales Hospital

  • Nancy Leung · Alice Ho Miu Ling Nethersole Hospital

  • Seng Gee Lim · National University Hospital, Singapore

  • Wan Cheng Chow · Singapore General Hospital

  • Sien-Sing Yang · Cathay General Hospital

  • I Shyan-Sheen · Chang Gung Memorial Hospital - Linko

  • Satawat Thongsawat · Maharaj Nakorn Chiang Mai Hospital

  • Tawesak Tandwandee · Siriraj Hospital

  • Man Fung Yuen · Queen Mary Hospital, Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2007-12-31

Countries

  • Hong Kong
  • Singapore
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00277576 on ClinicalTrials.gov